Accounts Payable and Accrued Expenses |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Expenses | Note 4 – Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consisted of the following:
As of September 30, 2026, $1,058,546 of remaining PharmAla license consideration payable was presented as a separate current liability and was not included in accounts payable and accrued expenses. See Note 6 - PharmAla License Agreement and Share-Settlement Liability for further discussion. Additionally, as of September 30, 2026 and December 31, 2025, there was accrued compensation of $528,616 and $1,397,357, respectively, which includes accrued salaries and health benefits to executives since inception and accrued board fees. Since inception, executive salaries have been paid in cash when the Company’s cash flow has permitted such payment and certain executive salaries related to 2022 and 2023 remain unpaid, following the partial forgiveness of accrued compensation on August 26, 2026, as further discussed in Note 3 – Related Party Transactions.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||